Conforma Therapeutics

What Conforma Therapeutics does

Conforma Therapeutics Corporation is a privately held, San Diego-based biopharmaceutical company founded in 1999 that designs and develops drugs for the treatment of cancer. The company's stated functional focus is on therapeutics design, but no product candidates, pipeline details, target indications, or underlying drug-discovery platform are disclosed in the available source material. Business model mechanics are not documented: pricing models, commercial partnerships, licensing arrangements, and revenue streams are all absent from the data set.

The company's investor base, assembled at a $30 million Series 3 financing in September 2003 led by SR One, included several notable life-sciences specialist investors (Domain Associates, Forward Ventures, Lilly Ventures, Novo Holdings, ProQuest Investments, RiverVest) and a capital-markets participant (RBC Capital Markets). No subsequent financing events, acquisitions, partnerships, leadership changes, or regulatory actions are recorded. The current headcount range of 1-10 employees and the corporate website (conformacorp.com), which displays only a verification/loading page, indicate that the company is either in a very low-activity state, dormant, or operating without public-facing disclosure. No customers, awards, patents, certifications, or geographic footprint are documented.

Name

Conforma Therapeutics

Website

https://conformacorp.com

Company type

Private

Founded year

1999

Headcount range

1–10 employees

Short description

Conforma Therapeutics is a privately held San Diego biopharmaceutical company founded in 1999 that designs and develops drugs for the treatment of cancer. The company has 1-10 employees and no disclosed products or pipeline.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API Process Development & Route Scouting (HLAGAHAA)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Cancer drug development
• Oncology therapeutics
• Small molecule drugs
• Pharmaceutical research
• Conformationally restricted drugs

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Core offering

Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. The company is a small-molecule oncology drug discovery venture, founded in 1999 and headquartered in San Diego, that applies proprietary drug design approaches to create novel anti-cancer therapeutics for out-licensing or partnership with larger pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncology drug candidates (cancer treatment drugs) Small-molecule drug candidates designed for the treatment of cancer, intended to be out-licensed, partnered, or co-developed with larger pharmaceutical companies.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• Blueprint Medicines: Precision therapy company developing targeted small-molecule kinase inhibitors for cancer. Comparable to Conforma as a small-molecule oncology drug developer with similar development-stage activities.
• Array BioPharma: Small-molecule oncology drug developer focused on targeted therapies for cancer. Was a direct comparable in the small-molecule oncology drug development space before its acquisition by Pfizer.
• Mirati Therapeutics: Clinical-stage oncology company developing targeted small-molecule therapies for cancer patients with genomically defined mutations. Directly comparable in small-molecule oncology drug development mandate.
• Deciphera Pharmaceuticals: Clinical-stage biopharmaceutical company developing switch-control kinase inhibitors for the treatment of cancer. Comparable in scope of small-molecule oncology drug development.
• Forma Therapeutics: Small-molecule oncology drug developer focused on targeting cancer biology and transcription factors. Directly comparable to Conforma's stated focus on designing and developing small-molecule cancer drugs.
• Constellation Pharmaceuticals: Clinical-stage biopharmaceutical company developing small-molecule modulators of epigenetic regulators for cancer therapy. Comparable as a small-molecule oncology drug developer targeting transcription and chromatin biology.
• Infinity Pharmaceuticals: Small-molecule oncology drug developer focused on developing novel therapeutics for cancer. Similar in scope and stage of small-molecule cancer drug development.
• Syros Pharmaceuticals: Biopharmaceutical company developing small-molecule therapies to address the unmet needs of patients with cancer and monogenic diseases. Comparable in small-molecule oncology drug development mandate.

Broad incumbents

• Lilly Ventures (Eli Lilly): Eli Lilly has a substantial oncology drug development program and was an investor in Conforma via Lilly Ventures. Comparable as a broad incumbent in oncology drug development with a connection to Conforma's historical funding.
• Pfizer Oncology: Large global pharmaceutical company with a substantial oncology franchise covering small molecules, biologics, and supportive care. Comparable as a major incumbent in oncology drug development and commercialization.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Conforma Therapeutics